Search results for "Normal"

showing 10 items of 2571 documents

One

2019

Neurofibromatosis type 1 (NF1) is an autosomal dominant disease with complete penetrance but high variable expressivity. NF1 is caused by loss-of-function mutations in the NF1 gene, a negative regulator of the RAS-MAPK pathway. The NF1 gene has one of the highest mutation rates in human disorders, which may explain the outbreak of independent de novo variants in the same family. Here, we report the co-occurrence of pathogenic variants in the NF1 and SPRED1 genes in six families with NF1 and Legius syndrome, using next-generation sequencing. In five of these families, we observed the co-occurrence of two independent NF1 variants. All NF1 variants were classified as pathogenic, according to t…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesSPRED1Neurofibromatosis 1Neurofibromin 1AdolescentCafe-au-Lait Spotsneurofibromatosis type 1eye diseasesArticlenervous system diseasesPedigreeLegius syndromePhenotypeNF1MutationHumansFemalede novo variantChildneoplasmsAdaptor Proteins Signal TransducingGenes
researchProduct

Sacral spina bifida occulta rare occurrence in Byzantine Belentepe population in Muğla, Turkey: A possible case for adequate folic acid intake.

2018

Spina bifida may occur during the first weeks after conception; folic acid deficiency is strongly related to this anomaly. We argue that the low prevalence rate of spina bifida may indicate a relatively good nutrition state of a population, given that folic acid is found in many food products commonly eaten. The aim of this study is to examine the relationship between folic acid intake and spina bifida occulta prevalence in the Belentepe Byzantine population in Anatolian peninsula, and to compare the prevalence rates with various other ancient Anatolian populations by focusing on sacral spina bifida occulta in the Byzantine population. A total of 62 available human sacra were included in th…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesSacrumAdolescentTurkeyPopulationPrevalenceNutritional StatusBiologyFolic Acid DeficiencySpina Bifida OccultaAnthropology PhysicalSpina bifida occultaYoung AdultmedicineHumanseducationChildHistory Ancienteducation.field_of_studySpina bifidaInfant NewbornInfantNutritional statusMiddle Agedmedicine.diseaseHistory Medievalnervous system diseasesFolic acidAnthropologyFood productsChild PreschoolFolic acid intakeFemaleByzantiumDemographyHomo : internationale Zeitschrift fur die vergleichende Forschung am Menschen
researchProduct

Novel rearrangements involving the RET gene in papillary thyroid carcinoma.

2018

Abstract Background In the field of gene fusions driving tumorigenesis in papillary thyroid carcinoma (PTC), rearrangement of the proto-oncogene RET is the most frequent alteration. Apart from the most common rearrangement of RET to CCDC6, more than 15 partner genes are yet reported. The landscape of RET rearrangements in PTC (“RET-PTC”) can notably be enlarged by modern targeted next-generation sequencing, indicating similarities between oncogenic pathways in other cancer types with identical genetic alterations. Methods Targeted next-generation sequencing was performed for two cases of BRAF-wild type PTC with confirmation of the results by Sanger sequencing. A “UniProt” database research …

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesendocrine systemCancer Researchendocrine system diseasesOncogene Proteins FusionBiologyRUN domainmedicine.disease_causeProto-Oncogene MasFusion gene03 medical and health sciencessymbols.namesake0302 clinical medicineGeneticsmedicineHumansThyroid NeoplasmsneoplasmsMolecular BiologyGeneSanger sequencingGene RearrangementProto-Oncogene Proteins c-retIntracellular Signaling Peptides and ProteinsCancerHigh-Throughput Nucleotide SequencingNuclear ProteinsProtein-Tyrosine Kinasesmedicine.diseaseLisH domainThyroid Cancer Papillary030220 oncology & carcinogenesisCancer researchsymbolsFemaleCarcinogenesisCarrier ProteinsTyrosine kinaseCancer genetics
researchProduct

Treatment of severe von Willebrand disease with a high‐purity von Willebrand factor concentrate (Wilfactin®): a prospective study of 50 patients

2007

Background and objectives: A plasma-derived von Willebrand factor (VWF) concentrate with low factor VIII (FVIII) content was specifically developed to treat von Willebrand disease (VWD). Efficacy and safety were investigated by merging the results of two comparable protocols conducted prospectively in 5 European and 12 French centers. Methods and results: Fifty patients with clinically severe VWD (72% had VWF ristocetin cofactor activity less than 10 IU dL(-1) and 46% had FVIII < 20 IU dL(-1)) were treated with the concentrate as the only therapy, except for clinical situations requiring a priming dose of FVIII to rapidly correct an intrinsic coagulation defect. A total of 139 spontaneous b…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyAdolescentHemorrhagePostoperative HemorrhageGastroenterologyVon Willebrand factorhemic and lymphatic diseasesInternal medicinevon Willebrand FactormedicineVon Willebrand diseaseHumansProspective StudiesChildProspective cohort studyAgedAged 80 and overHemostasisBleeding episodesFactor VIIIbiologybusiness.industryHematologyMiddle Agedmedicine.diseaseSurgeryClinical trialvon Willebrand DiseasesCoagulationChild PreschoolHemostasisConcomitantbiology.proteinFemaleSafetybusinessJournal of Thrombosis and Haemostasis
researchProduct

Abnormal Somatosensory Evoked Potentials Indicate Compressive Cervical Myelopathy in Mucopolysaccharidoses

2000

Compressive myelopathy at the cranio-cervical junction is a complication of mucopolysaccharidoses (MPS). To detect cervical myelopathy we recorded median and posterior tibial nerve SEPs in 15 patients aged 2.4 - 33.4 years (median 8.8 years) with MPS I-S (n = 3), MPS IVA (n = 8) and MPS VI (n = 4). In addition to the cortical waveforms we recorded the subcortical median nerve SEPs N13b and P13 generated near the cranio-cervical junction and the lemniscal P30 after posterior tibial nerve stimulation. MRI studies in 13 subjects revealed spinal cord compression at the cranio-cervical junction in 10 patients; 5 patients had an increased signal intensity on the T2-weighted initial MRI indicating…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyAdolescentSensitivity and SpecificityCentral nervous system diseaseMyelopathySpinal cord compressionEvoked Potentials SomatosensorymedicineHumansChildbusiness.industryGeneral MedicineCervical cord compressionMucopolysaccharidosesmedicine.diseaseSpinal cordMagnetic Resonance ImagingMedian nerveMedian NerveSurgerybody regionsmedicine.anatomical_structureSpinal CordSomatosensory evoked potentialChild PreschoolPediatrics Perinatology and Child HealthFemaleNeurology (clinical)RadiologyTibial NervebusinessSpinal Cord CompressionMyelomalaciaNeckNeuropediatrics
researchProduct

Prospective risk stratification of sudden cardiac death in Marfan's syndrome.

2013

Marfan syndrome (MFS) is a variable, autosomal-dominant disorder of the connective tissue. In MFS serious ventricular arrhythmias and sudden cardiac death (SCD) can occur. The aim of this prospective study was to reveal underlying risk factors and to prospectively investigate the association between MFS and SCD in a long-term follow-up.77 patients with MFS were included. At baseline serum N-terminal pro-brain natriuretic peptide (NT-proBNP), transthoracic echocardiogram, 12-lead resting ECG, signal-averaged ECG (SAECG) and a 24-h Holter ECG with time- and frequency domain analyses were performed. The primary composite endpoint was defined as SCD, ventricular tachycardia (VT), ventricular fi…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyCardiomyopathyVentricular tachycardiaRisk AssessmentSudden cardiac deathMarfan SyndromeYoung AdultInternal medicineClinical endpointMedicineHumanscardiovascular diseasesProspective StudiesUltrasonographybusiness.industryHazard ratioMiddle Agedmedicine.diseaseSignal-averaged electrocardiogramDeath Sudden CardiacVentricular fibrillationCardiologyFemaleTransthoracic echocardiogramCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesInternational journal of cardiology
researchProduct

Relationship Between Glucocerebrosidase Activity and Clinical Response to Enzyme Replacement Therapy in Patients With Gaucher Disease Type I

2018

The quantification of enzyme activity in the patient treated with enzyme replacement therapy (ERT) has been suggested as a tool for dosage individualization, so we conducted a study to evaluate the relationship between glucocerebrosidase activity and clinical response in patients with Gaucher disease type I (GD1) to ERT. The study included patients diagnosed with GD1, who were being treated with ERT, and healthy individuals. Markers based on glucocerebrosidase activity measurement in patients' leucocytes were studied: enzyme activity at 15 min. post-infusion (Act75 ) reflects the amount of enzyme that is distributed in the body post-ERT infusion, and accumulated glucocerebrosidase activity …

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyDiseaseToxicologySeverity of Illness IndexGastroenterology03 medical and health sciencesGlucocerebrosidase activity0302 clinical medicineStatistical significanceInternal medicineLeukocytesHumansMedicineEnzyme Replacement TherapyIn patientProspective Studies030212 general & internal medicineInverse correlationAgedEnzyme AssaysPharmacologyGaucher DiseaseDose-Response Relationship Drugbiologybusiness.industryArea under the curvenutritional and metabolic diseasesGeneral MedicineEnzyme replacement therapyMiddle AgedEnzyme assayTreatment Outcome030220 oncology & carcinogenesisbiology.proteinGlucosylceramidaseFemalebusinessBiomarkersFollow-Up StudiesBasic &amp; Clinical Pharmacology &amp; Toxicology
researchProduct

Transient hepatic nodular lesions associated with patent ductus venosus in preterm infants.

2010

We report on two cases of low-birth-weight preterm infants with patent ductus venosus associated with hepatic hypoechoic lesions of the fourth segment in an otherwise normal liver. Although tumorlike hepatic lesions have been previously reported in association with portosystemic shunts in children and adults, they were never described in preterm infants during physiological patency of ductus venosus. In our patients, hepatic lesions disappeared shortly after the spontaneous ductus closure. Physiopathologic interactions are discussed regarding altered portal blood supply caused by ductus venosus shunt.

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyGestational AgeHepatic VeinsSettore MED/38 - Pediatria Generale E SpecialisticaInternal medicinemedicineHumanscardiovascular diseasesUltrasonographyPATENT DUCTUS VENOSUSbusiness.industryFocal nodular hyperplasiaInfant NewbornPortosystemic shunt - focal nodular hyperplasia - focal fatty sparing - ultrasoundObstetrics and GynecologyInfant Low Birth Weightmedicine.diseaseSurgeryPortal SystemLiverNodular lesionsFocal Nodular HyperplasiaPediatrics Perinatology and Child HealthPortal bloodcardiovascular systemCardiologyFemalePortosystemic shuntbusinessShunt (electrical)Ductus venosusInfant PrematureLiver CirculationAmerican journal of perinatology
researchProduct

Distribution, genetic and cardiovascular determinants of FVIII:c - Data from the population-based Gutenberg Health Study

2015

Background: Elevated levels of FVIII:c are associated with risk for both venous and arterial thromboembolism. However, no population-based study on the sex-specific distribution and reference ranges of plasma FVIII: c and its cardiovascular determinants is available. Methods: FVIII:c was analyzed in a randomly selected sample of 2533 males and 2440 females from the Gutenberg Health Study in Germany. Multivariable regression analyses for FVIII:c were performed under adjustment for genetic determinants, cardiovascular risk factors and cardiovascular disease. Results and conclusions: Females (126.6% (95% CI: 125.2/128)) showed higher FVIII:c levels than males (121.2% (119.8/122.7)). FVIII:c le…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyLinkage disequilibriumGenotypeanimal diseasesPopulationFVIII:c reference valuesSingle-nucleotide polymorphismDiseaseAge DistributionVon Willebrand factorGermanyThromboembolismhemic and lymphatic diseasesInternal medicineVenous thrombosisHumansMedicineGenetic Predisposition to DiseaseProspective StudiesSex DistributioneducationAgededucation.field_of_studyEpidemiological studiesFactor VIIIPolymorphism Geneticbiologybusiness.industryIncidenceC-reactive proteinArterial thrombosisDNAMiddle AgedNomogrammedicine.diseaseVenous thrombosisPopulation SurveillanceImmunologybiology.proteinFemaleCardiology and Cardiovascular MedicinebusinessFollow-Up Studies
researchProduct

Outcome of type III Gaucher disease on enzyme replacement therapy: review of 55 cases.

2007

The European Task Force for Neuronopathic Gaucher Disease (NGD) met in 2006 to review its 2001 guidelines. Fifty-five patients from five European countries were reviewed; 29 were male and 26 female. The majority of the patients were homozygous for the L444P mutation. All had been on enzyme replacement therapy (ERT). However, there was considerable variation in the dose of ERT, as well as an uneven distribution of risk factors. Thus, the oldest patients were on the lowest doses, and several had had a total splenectomy, while the youngest patients had a high proportion of compound heterozygosity and were on the highest doses, and very few had had a splenectomy. This heterogeneity rendered ana…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyPediatricsHeterozygoteTime FactorsAdolescentmedicine.medical_treatmentSplenectomyEnzyme TherapyDiseaseCompound heterozygosityCentral nervous system diseaseOlder patientsRisk FactorsGeneticsmedicineTotal splenectomyHumansChildGenetics (clinical)Intelligence TestsChemotherapyGaucher Diseasebusiness.industryHomozygotenutritional and metabolic diseasesEnzyme replacement therapymedicine.diseaseSurgeryTreatment OutcomeChild PreschoolGlucosylceramidaseFemaleNervous System DiseasesbusinessJournal of inherited metabolic disease
researchProduct